<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736267</url>
  </required_header>
  <id_info>
    <org_study_id>MEEI HSC 12-061</org_study_id>
    <nct_id>NCT01736267</nct_id>
  </id_info>
  <brief_title>Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects</brief_title>
  <official_title>Study of Nucleus 24 and ABI541 Auditory Brainstem Implants (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether Auditory Brainstem Implant (ABI)
      can improve hearing in persons who are deaf in both ears and are not candidates for cochlear
      implants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this MEEI Auditory Brainstem Implant (ABI) research study is to find new ways to
      improve hearing in patients who are deaf and cannot receive a cochlear implant. The ABI is a
      surgically placed bionic implant that converts sounds into electrical signals that are
      directly transmitted to the cochlear nucleus, the first auditory center of the brain. For
      many years, ABIs have improved the hearing of patients who are deaf due to brain tumors
      associated with a genetic syndrome called Neurofibromatosis Type 2 (NF2). However, a number
      of recent studies suggest that deaf patients who do not have NF2 and are not eligible for a
      cochlear implant may also benefit from placement of an ABI. These preliminary studies suggest
      that these non-NF2 or &quot;nontumor&quot; patients may actually have better outcomes after ABI surgery
      than patients suffering from NF2. Patients who do not have NF2 and are deaf due to damage to
      the hearing nerves or inner ears from infection, disease or injury are not cochlear implant
      candidates and there are no other options to improve hearing in these cases except for the
      ABI. Thus, the purpose of our study is to carefully analyze whether ABI surgery improves the
      hearing and quality of life of non-NF2 patients based on subjective and objective measures of
      their hearing before and after ABI surgery. In particular, we plan to study ABI outcomes in
      non-NF2 patients, characterize the parameters used on their devices, and determine the safety
      profile of ABIs in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed by IRB
  </why_stopped>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">April 25, 2019</completion_date>
  <primary_completion_date type="Actual">April 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Audiologic Performance</measure>
    <time_frame>12 months post-operative</time_frame>
    <description>Average pure tone threshold measured 12 months post-operatively. Measured in dB HL, where a lower threshold indicates more sensitive hearing and a higher threshold indicates less sensitive hearing.
We only included data from subjects that had auditory percept of any magnitude following ABI surgery (1/3 subjects).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Bilateral Hearing Loss for Causes Other Than Tumors</condition>
  <arm_group>
    <arm_group_label>Non-NF2 ABI surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be part of a single arm involving placement of the Nucleus ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)</intervention_name>
    <description>Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.</description>
    <arm_group_label>Non-NF2 ABI surgery</arm_group_label>
    <other_name>ABI, Nucleus 24, Cochlear Americas, ABI541, Nucleus Profile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  English as the primary language

          -  Medically and psychologically suitable

          -  Willing to receive/have received meningitis / pneumococcal vaccinations

          -  Able to comply with study requirements, including travel to the investigational site

          -  Cochlear or retrocochlear anomaly/pathology that interferes with transmission of
             auditory information from the cochleae to the brainstem, resulting in severe to
             profound bilateral deafness (thresholds of 90 dB or worse in both ears on pure tone
             audiometry ranging from 250 to 2,000 Hz and speech recognition scores ≤ 30% in both
             ears). All subjects will undergo bone conduction audiometry and tympanometry to
             confirm sensorineural hearing loss and rule out potential middle ear disorders.

               -  Conditions that cannot be otherwise treated, with conventional hearing aids or
                  cochlear implants. If CI were previously used, subjects will have had a failed
                  response, defined as ≤ 30% speech recognition and patient perception of
                  inadequate benefit to continue using the device.

               -  Expected subjects include those with these diagnoses:

                    -  Bilaterally severe/completely ossified cochleae

                    -  Bilateral cochlear malformations leading to poor CI outcomes

                    -  Bilateral temporal bone fractures, where the VIIIth cranial nerves have been
                       disrupted

                    -  Bilateral cochlear nerve agenesis

                    -  Not a CI candidate based on above listed pathology, intolerable adverse
                       effects with CI (e.g. stimulation of the facial nerve), or Evoked Auditory
                       Potential testing predictive of a poor response

        Exclusion Criteria:

          -  Anomalies/pathology involving the brainstem or cortex

          -  Retrocochlear pathology due to NF2 or other types of cranial nerve or brainstem
             neoplasm

          -  Co-existing medical conditions that require irradiation of the brainstem or auditory
             cortex

          -  Medical or psychological conditions that serve as contraindication to surgery

          -  Additional handicaps that would prevent or limit participation in evaluations

          -  Unrealistic patient or family expectations regarding the benefits, risks, and
             limitations inherent to the procedure and the prosthetic device

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J Lee, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEEI, HMS, MGH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://otosurgery.org/index.html</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Colletti V, Shannon RV, Carner M, Veronese S, Colletti L. Complications in auditory brainstem implant surgery in adults and children. Otol Neurotol. 2010 Jun;31(4):558-64. doi: 10.1097/MAO.0b013e3181db7055.</citation>
    <PMID>20393378</PMID>
  </reference>
  <reference>
    <citation>Sennaroglu L, Ziyal I, Atas A, Sennaroglu G, Yucel E, Sevinc S, Ekin MC, Sarac S, Atay G, Ozgen B, Ozcan OE, Belgin E, Colletti V, Turan E. Preliminary results of auditory brainstem implantation in prelingually deaf children with inner ear malformations including severe stenosis of the cochlear aperture and aplasia of the cochlear nerve. Otol Neurotol. 2009 Sep;30(6):708-15. doi: 10.1097/MAO.0b013e3181b07d41.</citation>
    <PMID>19704357</PMID>
  </reference>
  <reference>
    <citation>Choi JY, Song MH, Jeon JH, Lee WS, Chang JW. Early surgical results of auditory brainstem implantation in nontumor patients. Laryngoscope. 2011 Dec;121(12):2610-8. doi: 10.1002/lary.22137.</citation>
    <PMID>22109761</PMID>
  </reference>
  <reference>
    <citation>Colletti V, Shannon R, Carner M, Veronese S, Colletti L. Outcomes in nontumor adults fitted with the auditory brainstem implant: 10 years' experience. Otol Neurotol. 2009 Aug;30(5):614-8. doi: 10.1097/MAO.0b013e3181a864f2.</citation>
    <PMID>19546832</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <results_first_submitted>April 23, 2020</results_first_submitted>
  <results_first_submitted_qc>April 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2020</results_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Dr. Daniel Lee</investigator_full_name>
    <investigator_title>Director of Auditory Brainstem Implant Progra, Department of Otolaryngology, Massachusetts Eye and Ear Infirmary</investigator_title>
  </responsible_party>
  <keyword>Auditory Brainstem Implant</keyword>
  <keyword>ABI</keyword>
  <keyword>Nucleus 24</keyword>
  <keyword>Deafness</keyword>
  <keyword>Hearing loss</keyword>
  <keyword>Non-tumor</keyword>
  <keyword>Non-NF2</keyword>
  <keyword>ABI541</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Bilateral</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 6, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT01736267/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-NF2 ABI Surgery</title>
          <description>Placement of an Auditory Brainstem Implant (ABI) device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-NF2 ABI Surgery</title>
          <description>Placement of an Auditory Brainstem Implant (ABI) device</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="36" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pure Tone Threshold Average (dB)</title>
          <units>dB HL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120" lower_limit="120" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Audiologic Performance</title>
        <description>Average pure tone threshold measured 12 months post-operatively. Measured in dB HL, where a lower threshold indicates more sensitive hearing and a higher threshold indicates less sensitive hearing.
We only included data from subjects that had auditory percept of any magnitude following ABI surgery (1/3 subjects).</description>
        <time_frame>12 months post-operative</time_frame>
        <population>We only included data from subjects that had auditory percept of any magnitude following ABI surgery (1/3 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-NF2 ABI Surgery</title>
            <description>Placement of an Auditory Brainstem Implant (ABI) device</description>
          </group>
        </group_list>
        <measure>
          <title>Audiologic Performance</title>
          <description>Average pure tone threshold measured 12 months post-operatively. Measured in dB HL, where a lower threshold indicates more sensitive hearing and a higher threshold indicates less sensitive hearing.
We only included data from subjects that had auditory percept of any magnitude following ABI surgery (1/3 subjects).</description>
          <population>We only included data from subjects that had auditory percept of any magnitude following ABI surgery (1/3 subjects).</population>
          <units>dB HL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All reported events occurred within one year of when the participant had surgery. Participants were followed through the end of their participation in the study for safety and continue to receive routine medical monitoring for safety as part of their standard care.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Non-NF2 ABI Surgery</title>
          <description>Placement of an Auditory Brainstem Implant (ABI) device</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>clear AD drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache, photophobia, stiff neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CSF collection</sub_title>
                <description>CSF collection with mild swelling post-surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>non-auditory side effects</sub_title>
                <description>non-auditory side effects after turning on device - &quot;pinching&quot; sensation in the leg</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Lee</name_or_title>
      <organization>Massachusetts Eye &amp; Ear Infirmary</organization>
      <phone>6175736391</phone>
      <email>Daniel_Lee@meei.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

